180 Life Sciences (NASDAQ: ATNF)
, a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has regained Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2). As previously disclosed on the January 2021
report on Form 8-K, the Listing Qualifications Department of the Nasdaq Stock Market LLC notified the company that it did not comply with the independent director and audit committee requirements for continued listing on the Nasdaq Capital Market set forth in Listing Rules 5605(b)(1) and 5605(c)(2). Nasdaq provided 180 Life Sciences 45 days, or until February 19, 2021, to submit to Nasdaq a plan detailing how the company intended to regain compliance with the rules. The company timely submitted such plan and Nasdaq granted an extension until June 30, 2021, for the company to regain compliance with the listing rules. On July 6, 2021, based on the appointments of Pamela G. Marrone to the 180 Life Sciences’ board of directors and Francis Knuettel II to its board and audit committee, as detailed in the current reports on Form 8-K filed by the company with the Securities and Exchange Commission on June 28, 2021
, and June 10, 2021
, Nasdaq provided written notice to the company that it complies with the rules, and this matter is now closed.
To view the full press release, visit https://ibn.fm/P1ozr
About 180 Life Sciences Corp.
180 Life Sciences
is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. 180 Life Sciences’ primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor). For more information, visit the company’s website at www.180LifeSciences.com
NOTE TO INVESTORS:
The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.